SuanFarma-Header SuanFarma-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): MigVax-101

            Therapeutic Area: Infections and Infectious Diseases Product Name: MigVax-101

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2021


            In the trial, tests carried out on rats demonstrated that the MigVax-101 sub-unit oral vaccine, when administered in a boost format following an injected S1 protein, elicited markedly higher neutralizing antibody titers than rats receiving an oral placebo booster.